WHO Prequalifies Novel Oral Polio Vaccine Type 2 (nOPV2)

• 14 Feb 2026

On 13th February 2026, the World Health Organization (WHO) prequalified a new novel oral polio vaccine type 2 (nOPV2) to accelerate global polio eradication efforts.

Key Points

• WHO Prequalification: Confirms the vaccine meets international standards of quality, safety, and efficacy, enabling procurement by UN agencies like UNICEF for immunization campaigns.
• Improved Genetic Stability: The nOPV2 vaccine is designed to be more genetically stable than earlier oral polio vaccines, reducing the risk of triggering new outbreaks.
• Boost to Eradication Efforts: Supports global campaigns to stop virus transmission and protect children in vulnerable regions.
• Global Funding Support: Follows a $1.9 billion pledge by global leaders to sustain eradication initiatives and protect around 370 million children annually.
• About Polio: A disabling and potentially life-threatening disease that has been eliminated in many regions but continues to circulate in some parts of the world.